We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord

Ticker
DWTX

Price
4.90
Stock movement up
+0.08 (1.65%)
Company name
Dogwood Therapeutics, Inc.
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Biotechnology
Markedsverdi
9.44M
Ent verdi
-
Pris/omsetning
-
Pris/bok
-
Utbytte avkastning
-
Utbytte vekst
-
Vekst år
-
FCF-utbetaling
-
Etterfølgende P/E
-
Fremtidig P/E
-
PEG
-
EPS-vekst
-
1 års avkastning
4.00%
3 års avkastning
-69.12%
5 års avkastning
-
10 års avkastning
-
Sist oppdatert: 2025-09-12

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

UTBYTTE

DWTX betaler ikke utbytte

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

VERDSETTELSE

Verdsettelsesforhold

Loading...
Verdsettelsesforhold-data
Etterfølgende P/E-
Pris til OCF-
Pris til FCF-
Pris til EBITDA-
EV i forhold til EBITDA-

Verdsettelse (Salg/Bokført verdi)

Loading...
Verdsettelse (Salg/Bokført verdi) data
Pris til omsetning-
Pris til bok-
EV i forhold til salg-

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

ØKONOMI

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

AKSJEINFORMASJON

Aksjediagram

Loading...
Aksjekurs-data
Åpning4.88
Daglig høy5.01
Daglig lav4.80
Daglig volum12K
Tidenes høyeste219.25
1 år analytikerestimat13.83
Beta1.94
EPS (TTM)-
Utbytte per aksje-
Ex-div dato-
Neste dato for resultatpresentasjon-

Nedsidepotensial

Loading...
Nedsidepotensial-data
DWTXS&P500
Nåværende prisfall fra toppnotering-97.75%-1.46%
Høyeste prisfall-99.16%-56.47%
Dato for høyeste fall18 Nov 20249 Mar 2009
Gj.snittlig fall fra topp-71.74%-10.99%
Gj.snittlig tid til ny topp69 days12 days
Maks tid til ny topp735 days1805 days

iO Charts is a Seeking Alpha partner

SELSKAPSOPPLYSNINGER
DWTX (Dogwood Therapeutics, Inc.) company logo
Markedsverdi
9.44M
Markedsverdi kategori
Small-cap
Beskrivelse
Dogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on the development of medicine to treat pain and fatigue-related disorders. Its lead product candidates include IMC-1, a fixed dose combination of famciclovir and celecoxib that has completed Phase 2b clinical trial to treat fibromyalgia; Halneuron, which is in Phase 2b clinical trial for the treatment of chemotherapy-induced neuropathic pain and cancer pain, as well as pre-clinical trial for burn and ocular pain; and IMC-2, a combination of valacyclovir and celecoxib in Phase 2 clinical trial for the treatment of long-COVID and post-acute sequelae of COVID-19 infection. The company was formerly known as Virios Therapeutics, Inc. and changed its name to Dogwood Therapeutics, Inc. in October 2024. The company was incorporated in 2012 and is based in Alpharetta, Georgia.
Ansatte
12
Investorrelasjoner
-
SEC-innsendelser
Adm. direktør
Land
USA
By
Aksjetype
-
CCC-status
-
Utbyttefrekvens
-
ARRANGEMENTER OG PRESENTASJONER
ArrangementerPresentasjoner
Loading...
FORSTÅ VIRKSOMHETEN
Loading...